Coronavirus Breaking News

The coronavirus disease COVID-19 is currently reaching pandemic levels in various countries.

Jan 31, 2021 • 12:59 pm CST

According to various governmental agencies, there are nine COVID-19 vaccines available globally. As of January 31, 2021, the COVID-19 vaccine development landscape includes innovative platforms such as DNA, RNA, virus-like particle, peptide, viral vector, recombinant protein, live attenuated virus, and inactivated virus approaches.

These innovative vaccines were initially developed in countries such as China, Germany, Russia, the United Kingdom, and the USA.

The latest COVID-19 vaccine to launch significant in-country distribution is the EpiVaxCorona vaccine produced in Russia. EpiVacCorona is an antigens-based vaccine that provokes an immune reaction against COVID-19 and promotes the further development of immunity.

Furthermore, from a total number of completed vaccinations, media reports indicate the Pfizer-BioNTech co-developed Comirnaty vaccine is the leader. Comirnaty is a nucleoside-modified RNA formulated in lipid nanoparticles and encodes an optimized SARS-CoV-2 full-length spike protein antigen.

Moreover, several experimental COVID-19 vaccines are approaching competition of their phase 3 studies, such as Johnson & Johnson. This news indicates the world will have additional COVID-19 vaccines available to choose from during 2021.

Medical Review by
Jan 31, 2021 • 7:58 am CST

To address the lack of access to tests and testing services in multiple countries, the World Health Organization (WHO) published on January 29, 2021, a yearly essential diagnostics list (EDL), a basket of recommended in vitro diagnostics that should be available at point-of-care and in laboratories in all countries to increase timely and life-saving diagnoses.

The latest edition includes WHO-recommended COVID-19 tests (PCR and Antigen), expands the suite of tests for vaccine-preventable and infectious diseases and non-communicable diseases (such as cancer and diabetes), and introduces a section on endocrinology, which is important for reproductive and women’s health. For the first time, the list includes tests that should not be supplied in countries, either because they are not cost-effective, unreliable, or surpassed by newer, easier to use technologies.

‘Access to quality tests and laboratory services is like having a good radar system that gets you where you need to go. Without it, you’re flying blind,’ said WHO Director-General, Dr. Tedros Adhanom Ghebreyesus, in a press statement. ‘All countries should pay particular attention to the diagnostics space and use the essential list to promote better health, keep their populations safe, and serve the vulnerable.’

The report follows the findings from the third meeting of the WHO Strategic Advisory Group of Experts on In-Vitro Diagnostics, which advises the Director-General of WHO in the area of diagnostics.

Medical Review by
Jan 31, 2021 • 7:12 am CST

The emerging variants the US Centers for Disease Control and Prevention (CDC) is closely monitoring have mutations in the coronavirus genome that alter the characteristics and cause the virus to act differently in ways that are significant to public health actions and treatments. It’s important to understand genetic mutations are expected, and some variants can spread and become predominant while others subside, says the CDC.

As of January 30, 2021, the U.S. CDC reported the following number of variant cases in 30 states:

  • UK B.1.1.7 = 434
  • South Africa B.1.351 = 2
  • Brazil P.1 = 1

The cases identified above are based on a sampling of SARS-CoV-2-positive specimens and do not represent the total number of B.1.1.7, B.1.351, and P.1 lineage cases that may be circulating in the USA and may not match numbers reported by states, territories, tribes, and local officials, says the CDC.

Medical Review by
Jan 30, 2021 • 1:55 pm CST

The European Union announced new rules regarding exports of COVID-19 vaccines on January 29, 2021. However, according to the AP News, the European Commission (EC) made clear the new measure will not trigger controls on COVID-19 vaccine shipments produced in the 27-nation union to parts of the United Kingdom (UK).

“The UK has legally-binding agreements with vaccine suppliers, and it would not expect the EU, as a friend and ally, to do anything to disrupt the fulfillment of these contracts,” the UK said.

Stella Kyriakides, the commissioner for health and food safety, Tweeted the EU is working with companies to ensure the vaccines are delivered. "It depends on all parties living up to their contractual, social, and moral responsibilities," she said.

These concerns are related to the European Commission granting a conditional marketing authorization (CMA) for the COVID‑19 vaccine developed by AstraZeneca, the third COVID-19 vaccine authorized in the EU.

The President of the EC, Ursula von der Leyen, said in a press release, “Securing safe vaccines for Europeans is our utmost priority. With the AstraZeneca vaccine now authorized, 400 million additional doses will be available in Europe. I expect the company to deliver these doses as agreed so that Europeans can be vaccinated as soon as possible. We will continue doing all we can to secure more vaccines for Europeans, our neighbors, and our partners worldwide.”

The AstraZeneca COVID-19 (AZD1222) coronavirus vaccine candidate is made from a virus (ChAdOx1), a weakened version of a common cold virus (adenovirus). Genetic material has been added to the ChAdOx1 construct, which is used to make proteins from the SARS-CoV-2 coronavirus called Spike glycoprotein.

Jan 30, 2021 • 8:29 am CST

The COVID-19 vaccine developed by the UK's AstraZeneca and the University of Oxford has been approved for use in Viet Nam's urgent situation, according to Minister of Health Nguyen Thanh Long. This is the first COVID-19 vaccine approved by Viet Nam.

Minister Long stated in a government press release issued on January 30, 2021, AstraZeneca pledged to supply 30 million vaccine doses for Viet Nam in 2021.

Vaccine research and development in Viet Nam has also launched.

The first stage of human trials of the home-grown vaccine, Nanocovax, began on December 17, 2020, while the second vaccine candidate, Covivac, launched on January 21, 2021.

After nearly two-months without reporting local COVID-19 cases, Viet Nam has confirmed an ongoing outbreak with 28 new cases of COVID-19 on January 30th, raising the patient tally to 1,767.

Medical Review by
Jan 30, 2021 • 7:57 am CST

The US Centers for Disease Control and Prevention (CDC), located in Atlanta, Georgia, issued an extensive Federal Order on January 29, 2021, requiring the wearing of face masks by travelers within the USA who are older than 1 year of age to prevent the coronavirus's spread that causes COVID-19.

This CDC Order becomes effective on February 1, 2021.

This Order must be followed by all passengers on public conveyances (e.g., airplanes, ships, ferries, trains, subways, buses, taxis, ride-shares) traveling into, within, or out of the USA, as well as conveyance operators (e.g., crew, drivers, conductors, and other workers involved in the operation of conveyances) and operators of transportation hubs ( e.g., airports, bus or ferry terminals, train or subway stations, seaports, ports of entry) or any other area that provides transportation in the United States.

Furthermore, travelers must wear masks covering both the mouth and nose when awaiting, boarding, traveling on, or disembarking public conveyances. People must also wear masks when entering or on the premises of a transportation hub in the USA.

According to the CDC, this Federal Oder signed by Dr. Martin S. Cetron, the new Director of the Division of Global Mitigation and Quarantine, will be enforced through criminal penalties by Federal Authorities and other appropriate agencies.

Jan 29, 2021 • 4:31 pm CST

The U.S. CDC published Key Updates for Week #3, ending January 23, 2021, which include national surveillance indicators tracking levels of SARS-CoV-2 circulation, associated illnesses, and hospitalizations remain elevated but show decreasing trends in recent weeks.

During week #3, the percentage of specimens testing positive for SARS-CoV-2 decreased in all regions. The overall percentage of respiratory specimens testing positive for SARS-CoV-2 decreased from 12.0% to 11.0% during week #3.

Both COVID-19-associated hospitalizations and pneumonia, influenza, and COVID-19 (PIC) mortality for the most recent weeks are expected to increase as the CDC receives more data.

Among 16,006 sampled adults hospitalized during March - October 31, 2020, with information on underlying medical conditions, 90.5% had at least one reported underlying medical condition. The most-reported underlying medical conditions were hypertension (55.8%), obesity (48.5%), metabolic disease (41.3%), which includes diabetes, and cardiovascular disease (32.5%).

Among 996 children hospitalized during March - October 31, 2020, with information on underlying conditions, 52.0% had at least one reported underlying medical condition. The most-reported underlying medical conditions were obesity (37.6%), neurologic disease (13.3%), and asthma (11.1%).

Medical Review by
Jan 29, 2021 • 12:40 pm CST

Canada's Prime Minister Justin Trudeau announced on January 29, 2021, certain airlines have agreed to suspend service to destinations in the Caribbean and Mexico, starting the 29th, until April 30, 2021.

"With the challenges we currently face with the COVID-19 pandemic, both here at home and abroad, we all agree that now is just not the time to be flying," said Trudeau outside his home at Rideau Cottage.

Furthermore, Trudeau stated 'Air Canada, WestJet, Sunwing, and Air Transat airlines will be making arrangements with their customers currently in these regions to organize flights home.

And starting in February, all international passenger flights will land at the Vancouver, Toronto, Calgary, and Montreal airports, said Trudeau. This change includes flights from the USA.

The prime minister also announced the Canadian government would be introducing mandatory PCR testing at airports for people returning to Canada, on top of the pre-boarding test requirements already mandated. Travelers will then have to wait up to three days at an approved hotel for their test results, at their own expense, which Trudeau said is expected to be more than $2,000.

Those with a negative test will then be able to finish their 14-day quarantine at home, with increased surveillance.

On January 28, 2021, the Public Health Agency of Canada issued the following statement: 'As COVID-19 activity continues in Canada, we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health, laboratory, and healthcare capacity.'

'The latest national-level data indicate a recent downward trend in daily case counts. While this suggests that community-based measures may be starting to take effect, it is too soon to be sure that current measures are strong enough and broad enough to maintain a steady downward trend.'

Medical Review by
Jan 29, 2021 • 11:21 am CST

The AP reported Hungary’s medicine and food safety regulator approved Sinopharm COVID-19 vaccine BBIBP-CorV for emergency use on January 29, 2021, making it the first country in the European Union to do so.

Hungary’s new vaccine approval procedure includes any vaccine that has been administered to at least one million people worldwide may now be approved for use in Hungary without being assessed by the country’s medicines regulator.

China-based Sinopharm's BBIBP-CorV COVID-19 is an inactivated vaccine made of virus particles grown in culture and lack disease-producing capability. This vaccine candidate was developed by Sinopharm’s Wuhan Institute of Biological Products Co. and the Chinese Center for Disease Control and Prevention. On December 31, 2020, China's National Medical Products Administration announced the experimental vaccine was approved.

Medical Review by
Jan 29, 2021 • 8:18 am CST

The Russian Direct Investment Fund (RDIF) announced on January 29, 2021, the registration of the Russian vaccine against coronavirus Sputnik V by the National Administration of Pharmaceuticals and Medicines of the Republic of Guinea. The Republic of Guinea is the second African country to approve the Sputnik V vaccine.

The vaccine was registered as part of an emergency use authorization based on Sputnik V clinical trials in Russia.

Kirill Dmitriev, CEO of the RDIF, said in a press statement, “The Republic of Guinea became the second African state to register the Sputnik V vaccine. High safety and efficacy rates make Sputnik V one of the most demanded vaccines against coronavirus on all continents."

"The drug was created on the well-studied human adenoviral vectors platform and is highly trusted by our partners in the Republic of Guinea. The Sputnik V vaccine was vaccinated by the President of the Republic, Alpha Conde. We welcome the regulator's decision to approve the vaccine and stand ready to support the Republic of Guinea in the fight against the pandemic."

Sputnik V is also registered in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, and the United Arab Emirates.

Medical Review by
Jan 28, 2021 • 5:03 pm CST

The U.S. Centers for Disease Control and Prevention (CDC) stated on January 28, 2021, it 'is aware that the first documented cases of the B 1.351 variant of SARS-CoV-2 have been identified in South Carolina. At this time, the CDC has no evidence that infections by this variant from South Africa cause more severe disease. Like the UK and Brazilian variants, preliminary data suggests the South African variant may spread more easily and quickly than other coronavirus variants.

Monitoring variants is why CDC has expanded National SARS-CoV-2 Strain Surveillance and will continue working with national reference laboratories, state health departments, and researchers from around the country to gather sequence data and increase genomic use sequencing data in response to the COVID-19 pandemic.

The CDC recommends that people avoid travel at this time. However, additional measures have been put in place to increase safety for those who must travel.

Effective January 26, 2021, the CDC requires all air passengers two years of age and over entering the USA (including U.S. citizens and Legal Permanent Residents) to present a negative COVID-19 test, taken within three calendar days of departure​, or proof of recovery from the virus within the last 90 days.

Medical Review by
Jan 28, 2021 • 11:46 am CST

The Russian Federation's capital city of Moscow, with about 12 million residents, has lifted certain COVID-19 pandemic restrictions, such as work-from-home and restaurant guidelines. Moscow's Mayor Sergei Sobyanin stated he signed a decree on January 27, 2021, which eliminated the requirement to transfer at least 30% of employees to remote work.

And restrictions on night work of catering establishments, night clubs, bars, discos, karaoke, bowling alleys, and other leisure and entertainment industry organizations are also canceled in Moscow. The Moscow Government will decide on changes at universities in early February 2021.

Throughout the COVID-19 pandemic, The Moscow Times reported Russia had confirmed 3,793,810 cases of coronavirus and 71,651 related fatalities.

Medical Review by
Jan 28, 2021 • 10:27 am CST

The Socialist Republic of Vietnam's Prime Minister Nguyen Xuan Phuc confirmed 82 new community infection cases of COVID-19 on January 28, 2021. Vietnam had gone 55 days without reporting local infections.

All of the latest COVID-19 patients are in Vietnam's northern provinces of Hai Duong and Quang Ninh. The Prime Minister ordered the subordinate levels to continue strict measures, including not allowing Hai Duong and Quang Ninh residents to leave their localities.

In Chi Linh, residents are asked to stay at home and only leave their places for essential needs such as buying food and medicines or medical emergencies, go to work at agencies, factories, businesses, and services establishments not told to close down, and other emergencies. And a gathering of more than two people is not allowed outside agencies, places of residence, schools, and hospitals.

Medical Review by
Jan 28, 2021 • 9:24 am CST

According to local media reporting on January 28, 2021, the Comirnaty vaccine shows 92% effectiveness in Israel. Only 31 out of 163,000 Israelis vaccinated by Maccabi Healthcare Services caught coronavirus in their first 10 days of full-strength protection, its top vaccine statistics analyst, Anat Ekka Zohar, told The Times of Israel. In an equivalent sample of unvaccinated Israelis, some 6,437 were diagnosed in the same timeframe.

Additionally, the Israeli Ministry of Health's Director-General Prof. Chezy Levy issued guidance 'to lower the vaccinated population's age to 35 and older effective January 28, 2021.

Germany-based BioNTech and Pfizer co-developed the Comirnaty (BNT162b2) vaccine to prevent severe COVID-19. Comirnaty is a nucleoside-modified RNA formulated in lipid nanoparticles and encodes an optimized SARS-CoV-2 full-length spike protein antigen.

Medical Review by
Jan 28, 2021 • 8:00 am CST

Saint-Herblain based Valneva SE announced on January 28, 2021, it has commenced production of its inactivated, adjuvanted COVID-19 vaccine candidate in parallel to the ongoing clinical studies to optimize the timeline for potential deliveries of the vaccine. VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe.

Additionally, Valneva confirmed the Phase 1/2 clinical study of 150 healthy adults aged 18 to 55 years is now fully enrolled and is expected to report initial results in April 2021.

Thomas Lingelbach, Valneva's CEO, said in a press statement, “We are extremely pleased to have achieved these two important milestones in such a short period of time. Our team in Scotland have done an amazing job to get manufacturing started so quickly."

"I would like to thank the UK Vaccines Taskforce and the National Institute for Health Research who played vital roles in the rapid recruitment and enrollment of the volunteers for the clinical study. We believe that our vaccine, assuming successful development, can make a major contribution in the UK and beyond.”

In September 2020, Valneva announced a partnership with the UK government to supply up to 190 million doses of its VLA2001 vaccine. Under this partnership agreement, if the vaccine development is successful, Valneva will provide the UK government with 60 million doses in the second half of 2021.

Valneva also announced in January 2021 it is in advanced discussions with the European Commission for the supply of up to 60 million doses of VLA2001.

Medical Review by